Multiple Myeloma: Combination Therapy of BET Proteolysis Targeting Chimeric Molecule with CDK9 Inhibitor
S. L. Lim, P. Koeffler, L. Xu, B. C. Han, P. Shyamsunder, W. J. Chng
This study shows that combining a BET PROTAC (ARV 825) with a CDK9 inhibitor (AZD 4573) effectively reduces multiple myeloma cell viability and induces apoptosis.
bioRxiv · Apr 8, 2020Cancer Biology